Bubendorf, Switzerland, June 2016 — CIS Pharma has developed a novel multipurpose solution for contact lenses. With over 25 years of experience and a track record of several lens care products licensed to and sold by partners globally, the team has developed the next generation contact lens care solution that increases contact lens wear comfort while keeping the efficacy of the product. The formulation combines unsurpassed high concentrations of hyaluronic acid without effecting the disinfection potential of the products. The products increase the wear comfort and support the health of the eye. In addition, they are highly effective against harmful bacteria, fungi and acanthamoeba. Long-term stability studies are currently being performed.

About contact lens care

Contact lenses are medical devices and must be treated carefully. If lenses pick up dirt, they may transfer bacteria that can cause serious infections to the cornea. A multipurpose contact lens care solution effectively kills harmful bacteria and fungi while the lenses are stored. This is achieved by a mixture of powerful anti-infectives. In addition, multipurpose solutions remove various deposits such as lipid and protein aggregates from the lens surface. Other agents in multipurpose solutions are responsible for rewetting the lens to restore the wear comfort.

About CIS Pharma AG

CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. CIS Pharma is located in the life science cluster of Basel, Switzerland. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of currently used medical treatments. For more information about the company, visit our website www.cis-pharma.com. — Discovery is our business, progress our passion.